World-class
Scientific Advisory

Work with Richmond Pharmacology and trust your experience will be personal and truly strategic.

Dr Jorg Taubel, MD FFPM FESC
Chief Executive Officer and Founder

Dr Jorg Taubel is medical practitioner and CEO of Richmond Pharmacology, a centre of excellence for experimental medicine studies, which he co-founded in 2001. A specialist in clinical pharmacology, Dr Taubel has extensive experience in cardiology, neurology, gastroenterology, and ethnic bridging studies. He was Principal Investigator in over 500 clinical trials in Phases 1 – 3. He is an MHRA recognised investigator for First in Human trials involving healthy and/or patient participants.

Most recently Dr Taubel has dosed the first patient in a global FIH study of NTLA-2001, the first CRISPR-Cas9 in vivo gene editing for transthyretin (TTR) amyloidosis.

Dr Taubel also established the Richmond Research Institute, a not-for-profit organisation dedicated to academic research to improve and save lives.

Education

Educated in Frankfurt, Germany, Dr Jorg Taubel graduated in medicine at Goethe-Universität in 1987 and achieved a postgraduate M.D in cardio-psychology awarded by the same university. In 1999, Dr Taubel was awarded a Diploma in Pharmaceutical Medicine by the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians.

Research

Dr Jorg Taubel is a research fellow at the Molecular and Clinical Sciences Research Institute at St George's University of London.  He has a special interest in cardiac repolarisation changes related to iatrogenic interference with glucostasis.

Recently, Dr Taubel was the Principal Investigator in the first clinical trial to study a novel antisense therapy targeting microRNA-132 with heart failure patients. The successful Phase 1b study was conducted directly in the target population. The findings were published in the European Heart Journal. He is also the Principal Investigator in first-in-human studies for hypertension, diabetes and NASH.

Dr Taubel first proposed to utilise the physiological ECG changes following a meal to establish assay sensitivity in thorough QT studies; this may be accepted by the FDA as an alternative to the pharmacological challenge with moxifloxacin (Taubel 2012). He has studied the effects of meals on cardiac repolarisation and the underlying autonomic and humoral effects on cardiac ion channels in healthy and patient populations (Taubel 2019).

Dr Taubel has authored over 150 publications in peer reviewed journals and presented his research at international events in Europe, Japan and the USA. He is a peer reviewer for various journals including the British Journal of Clinical Pharmacology, Clinical Pharmacology in Drug Development and New England Journal of Medicine.

Awards and honours

Dr Taubel is a Fellow of the European Society of Cardiology (ESC), the Faculty of Pharmaceutical Medicine (FPM) of the Royal Colleges of Physicians of the United Kingdom, the Royal Society of Medicine and the Institute of Directors (IOD).

He is a Regent in the Arbeitsgemeinschaft Angewandte Humanpharmakologie (AGAH), and a member of the British Pharmacological Society (BPS). As a board member of the (British) Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI) and the European Federation for Exploratory Medicines Development (EUFEMED), Dr Taubel has been on the programme committees for annual meetings from 2015.

His international memberships include the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT), the American College of Clinical Pharmacology (ACCP), the American Society of Pharmacology and Therapeutics (ASCPT), and the Drug Information Association (DIA).

He teaches students and trains doctors working at Richmond Pharmacology who are enrolled in Specialist Training in Pharmaceutical Medicine. He is also the Responsible Officer for Richmond Pharmacology.

Back to experts
r-gate

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Making gains in drug development

September 2, 2021
Keith Berelowitz outlines the innovations in the design and delivery of clinical trials
Read more

Inclisirin hailed as a 'gamechanger' gains approval for NHS patients

September 2, 2021
This novel therapeutic drug has potential to impact millions at risk of heart attack and stroke.
Read more

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more